Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immediate early response 2 protein (IER2)
- Target
- IER2
- Molecular classification
- Transcription factor, Immediate-early protein, DNA-binding protein, Trans-activator
01
Overview
Immediate early response 2 protein (IER2) is a DNA-binding transcription factor implicated in the early cellular response to diverse external stimuli. It regulates transcription by RNA polymerase II and is involved in the modulation of cell motility, cell-matrix adhesion, actin cytoskeleton rearrangement, and angiogenesis. IER2 also plays a role in neuronal differentiation and is involved in tumor progression and metastasis, notably in colorectal and hepatic cancers. It functions via JNK signaling and acts as a potential biomarker in several malignancies, including acute myeloid leukemia, colorectal adenocarcinoma, hepatocellular carcinoma, and melanoma.
- Other names
- CHX1Ch1ETR101ETR11Pip92T lymphocyte activatedimmediate early response 2protein ETR101chxI protein homologPIP92immediate early response gene 2 protein
02
Biological functions
Regulation of cell motilityRegulation of cell adhesionAngiogenesisRegulation of actin cytoskeletonPositive regulation of transcription by RNA polymerase IINeuronal differentiationNeurite outgrowthJNK signaling pathway activation
03
Disease associations
CancerColorectal cancerHepatocellular carcinomaMelanomaChildhood acute myeloid leukemiaTumor metastasis
04
Safety considerations
Associated with tumor progression and metastasis, which can represent challenges for safety or off-target effects in therapeutic targeting
05
Biomarkers
Biomarker for childhood acute myeloid leukemiaBiomarker for colorectal adenocarcinomaBiomarker for hepatocellular carcinomaBiomarker for melanoma
Beyond the preview
Go deeper on Immediate early response 2 protein (IER2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immediate early response 2 protein (IER2).